IMF-001 Phase 1 Study With Refractory Esophageal Tumor.

Trial Profile

IMF-001 Phase 1 Study With Refractory Esophageal Tumor.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs IMF 001 (Primary)
  • Indications Oesophageal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Planned end date changed from 1 Mar 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top